Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	41.21B -8.6%
Revenue (ttm)	7.95B -4.7%
Net Income	1.83B -0.2%
EPS	0.28 -1.9%
Shares Out	6.60B
PE Ratio	22.68
Forward PE	18.49
Dividend	0.03 (0.49%)
Ex-Dividend Date	Feb 10, 2026

Volume	22,857,489
Average Volume	37,344,043
Open	6.28
Previous Close	6.28
Day's Range	6.24 - 6.29
52-Week Range	6.23 - 7.30
Beta	0.44
RSI	39.16
Earnings Date	Mar 27, 2026

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The company was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.